Evidence map›Paper›PMID 41495781›Full record

ArticleJournal of hematology & oncology2026

Multiple myeloma risk linked to DNA damage response genes.

Michael Conry, Irina Ostrovnaya, Yelena Kemel, Saloni Sinha, Linda B Baughn, Brian Avery, Kylee Maclachlan, Victoria Groner, Lauren Banaszak, Aaron Norman and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Michael ConryClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Irina OstrovnayaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena KemelClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Saloni SinhaClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Linda B BaughnDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Brian AveryDepartment of Internal Medicine, Huntsman Cancer Institute University of Utah, Salt Lake City, UT, USA.
Kylee MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Victoria GronerClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lauren BanaszakClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aaron NormanDepartment of Quantitative Health Science Research, Mayo Clinic, Rochester, MN, USA.
Nicholas J BoddickerDepartment of Quantitative Health Science Research, Mayo Clinic, Rochester, MN, USA.
Alyssa Clay-GilmourDepartment of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Shaji KumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Ellen KimClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sita DandikerClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mitul WaghmareClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Susan SlagerDepartment of Quantitative Health Science Research, Mayo Clinic, Rochester, MN, USA.
Douglas W SborovDepartment of Internal Medicine, Huntsman Cancer Institute University of Utah, Salt Lake City, UT, USA.
Judy GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth E BrownDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Michelle HildebrandtDepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Parameshwaran HariDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Nicola Camp *Department of Internal Medicine, Huntsman Cancer Institute University of Utah, Salt Lake City, UT, USA.
Celine Vachon *Department of Quantitative Health Science Research, Mayo Clinic, Rochester, MN, USA.
Saad Usmani *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth Offit *Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vijai Joseph *Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. josephv@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
GENETIC EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIAR01CA134674 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J. · 2010 to 2016
$3.8M
Epigenetic contribution to the excess risk of MGUS in African AmericansU01CA249955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BROWN, ELIZABETH E · 2021 to 2025
$3.0M
Molecular characterization of myeloma and related asymptomatic precursor statesR01CA186646 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BROWN, ELIZABETH E, VACHON, CELINE M · 2014 to 2018
$3.0M
InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies.U01CA257679 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI CLAY-GILMOUR, ALYSSA IONE, HJALGRIM, HENRIK · 2021 to 2025
$2.7M
Candidate Gene Resequencing of Germline Multiple MyelomaR21CA209533 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOSEPH, VIJAI · 2017 to 2018
$443k
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA134674NCI NIH HHS R01 CA186646NCI NIH HHS R21 CA209533NCI NIH HHS U01 CA249955NCI NIH HHS U01 CA257679NHLBI NIH HHS HHSN268201700006CNIH HHS R01CA134674NIH HHS R21CA209533NIH HHS U01CA249955 , R01CA186646NIH HHS U01CA257679
6 · The paper itself

Abstract

backgroundDNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).

methodsHerein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.

resultsIncreased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival.

conclusionsOur results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.

Indexed as

DNA DamageGenetic Predisposition to DiseaseMultiple MyelomaAgedCase-Control StudiesFemaleGerm-Line MutationHumansMaleMiddle AgedRisk FactorsCancer geneticsCancer Predisposition SyndromesCancer PreventionFamilial Hematologic MalignanciesGenetic Risk FactorsGermline PredispositionPlasma Cell NeoplasmsRare Pathogenic VariantsRare variantsSurvival and Prognostic Biomarkers

Identifiers

PMID41495781
PMCPMC12810017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.